Jiangsu Recbio Shoots to Become Hong Kong’s First HPV Vaccine Stock
The vaccine producer is making a second attempt to list in Hong Kong, as its core HPV vaccine undergoes Phase 3 clinical trials Key takeaways: Jiangsu Recbio has filed a…
RELATED ARTICLES
-
Health Guard plans dual listing to fund HPV vaccine fight
- China’s mRNA pioneer Stemirna faces post-Covid reinvention test
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
-
HBM gets health boost from drug licensing deals
2142.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
